|
Investing Ideas from the Cutting Edge of Biotech
Kapitall Blog (blog) It has a potentially better follow-on to Roche/Genentech’s old monoclonal antibody Rituxan (rituximab). Roche’s monoclonal antibody Gazyva (obinutuzumab; GA101) was recently approved and we believe provides important validation to TG’s ublituximab, … |
NIH Study Finds Low-Intensity Therapy For Burkitt Lymphoma Is Highly EffectiveRedOrbitNineteen HIV-negative patients received dose-adjusted (DA)-EPOCH-R, whereas 11 HIV-positive patients received SC-EPOCH-RR, which is a short-course (SC) variant of EPO…
Risk factors for Coxiella burnetii antibodies in bulk tank milk from Danish …7thSpace Interactive (press release)Risk factors for Coxiella burnetii antibodies in bulk tank milk from Danish dairy herds. The aim was to identify risk factors associated …
|
Cyclophosphamide and rituximab combo reduced severe lupus flares
Skin and Allergy News Digital Network SAN DIEGO – The combination of intravenous cyclophosphamide and rituximab shows promise for the reduction of lupus flares, both renal and nonrenal, in patients with severe systemic lupus erythematosus, according to Dr. Ali Shahzad. Moreover, this … |
INNATE PHARMA : preclinical data opening new perspectives for development …GlobeNewswire (press release)Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated, antibody-depende…
|
ADC Therapeutics Licenses Proprietary Antibodies from Five Prime …
HispanicBusiness.com By a News Reporter-Staff News Editor at Investment Weekly News — ADC Therapeutics Sarl (‘ADC Therapeutics’), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates … |
|
Low-Dose Therapy for Burkitt’s Passes Muster
MedPage Today Investigators examined two similar regimens: standard dose-adjusted EPOCH-R (DA-EPOCH-R) for HIV-negative patients and short-course therapy with a double dose of rituximab (SC-EPOCH-RR). Patients treated with DA-EPOCH-R continued therapy for … NIH study finds low-intensity therapy for Burkitt lymphoma is highly effectiveEurekAlert (press release) Low-intensity chemo works for Burkitt’s lymphomaThe Oncology Report Low-intensity EPOCH-R regimen effective in immunodeficiency-associated …Healio |
|
TG Therapeutics, Inc. (TGTX): TG Therapeutics’ CEO Discusses Q3 2013 Results …
Seeking Alpha The third preclinical poster will demonstrate the activity of 1202 in Hodgkin’s lymphoma cell lines as a single agent as well as in combination with rituximab and anti-CD 30 conjugated monoclonal antibody approved for patients with Hodgkin’s lymphoma … |
|
Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1
Seeking Alpha … submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin’s lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. |
Maine Biotechnology Services-USDA-ARS Partnership Provides Monoclonal …PR Web (press release)Monoclonal antibodies specific to Rift Valley Fever Virus developed by Maine Biotechnology Services, in partnership with the USDA-Agricultural Research Servi…